Miudella (Sebela), a copper intrauterine device (IUD), has been approved by the FDA for prevention of pregnancy for up to 3 years. Miudella is the second copper IUD to be approved in the US; ParaGard, which contains more copper and is approved for up to 10 years of use, was approved in 1984. Four hormonal IUDs (Mirena, Liletta, Skyla, Kyleena) that release the progestin levonorgestrel are also available for pregnancy prevention (see Table 2).1
IUDs — IUDs are highly effective in preventing pregnancy....
RELEASE
Fitusiran (Qfitlia – Sanofi), a subcutaneously injected, antithrombin-directed, small interfering ribonucleic acid (siRNA), has been approved by the FDA for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients ≥12 years old who have hemophilia A with or without factor VIII inhibitors or hemophilia B with or without factor IX inhibitors. It is the first antithrombin-lowering therapy to become available in the US for treatment of hemophilia.
STANDARD TREATMENT ― Hemophilia A is an X-linked bleeding disorder (estimated prevalence 1:5000 live male births) characterized by insufficient levels of coagulation factor VIII. Prophylaxis with intravenous factor VIII replacement therapy is the standard of care, but >30% of patients with severe hemophilia A develop neutralizing antibodies (inhibitors) to factor VIII and require alternative treatments.
…